On May 31, 2024, Moderna announced that it received FDA marketing approval for its RSV mRNA vaccine. mRNA-1345, the “first marketed non-COVID-19 mRNA vaccine” to be used for the prevention of RSV-associated lower respiratory tract disease(RSV-LRTD) and acute respiratory disease (ARD) in adults aged 60 years or older.
mRNA-1345 is an mRNA vaccine encodes a viral stable pre-fusion F glycoprotein, that elicits a superior neutralizing antibody response compared to the post-fusion state. It is also being delivered with the same lipid nanoparticles (LNP) as Moderna’s Covid-19 vaccine and contains optimized protein and codon sequences to improve the stability and efficacy of the mRNA vaccine.
As a platform technology, mRNA has the advantages of simple production process, short production cycle, high flexibility, etc. It has the potential to encode almost all proteins and has a broad application prospect. Moderna’s rapid launch of the RSV mRNA vaccine after the Covid-19 mRNA vaccine has once again confirmed the potential of mRNA vaccines.
In the R&D cycle of mRNA vaccines & drugs, the most critical steps for early target screening and validation include:
a)sequence design
b)preparation of DNA templates
c)stock solutions
With the advantage of platform technology, it is possible to design and optimize as many and as complete solutions for potential targets as possible, and to screen for the most suitable sequence solutions.
Based on its in-depth research and rich experience in mRNA vaccines & drugs, Hyasen provides target sequence design, high-quality mRNA plasmid template preparation, IVT process optimization and target proof-of-concept, etc. We can help customers to quickly obtain the mRNA stock solution of the potential target and verify the feasibility of the target, and accelerate the project cycle. Compared with traditional vaccine and drug early target validation, the experimental cycle and cost are greatly reduced.
Post time: Jun-04-2024
